导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.49% | 211/4773 |
| 近一周 | -1.63% | 607/5462 |
| 近一月 | -5.78% | 3355/5421 |
| 近一季 | -5.43% | 1842/5209 |
| 近半年 | 15.92% | 251/4920 |
| 近一年 | 29.72% | 195/4366 |
| 近两年 | 161.09% | 156/2954 |
| 近三年 | 101.58% | 130/2253 |
| 成立以来 | 79.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.99% 2988/4961 |
69.47% 293/5312 |
- - |
- - |
| 2025 | 49.22% 492/4813 |
8.82% 430/3635 |
1.26% 2402/4076 |
38.10% 865/4524 |
-1.94% 3041/4813 |
| 2024 | 11.60% 1311/3463 |
-10.15% 2318/2808 |
-2.76% 1245/3014 |
16.30% 1486/3129 |
9.83% 305/3463 |
| 2023 | 2.39% 321/2656 |
25.54% 98/2280 |
-7.52% 1860/2385 |
-10.84% 2027/2515 |
-1.08% 283/2655 |
| 2022 | -29.46% 1602/2207 |
-21.93% 1668/1919 |
-0.35% 1618/2016 |
-13.16% 850/2113 |
4.42% 548/2208 |
| 2021 | 14.52% 330/1822 |
-8.82% 1095/1255 |
18.06% 176/1330 |
-3.78% 660/1466 |
10.57% 101/1822 |
| 2020 | 7.33% 867/1250 |
-0.15% 180/1028 |
19.32% 301/1067 |
-2.78% 1081/1164 |
-7.34% 1156/1184 |
| 2019 | 68.40% 31/1092 |
46.33% 21/754 |
-9.53% 663/804 |
16.56% 14/850 |
9.13% 256/918 |
| 2018 | -31.52% 497/834 |
- - |
- - |
- - |
-14.68% 590/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证500信息技术联接C VS. 长安沪深300非周期A(740101) |